Pyrimidine compounds and methods of making and using same
View Patent ↗Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.
1. A compound of formula I:
including a pharmaceutically acceptable salt, prodrug or N-oxide thereof, wherein:
X 2 is CR 2 or N, X 3 is CR 3 or N, X 4 is CR 4 or N, X 5 is CR 5 or N, and X 6 is CR 6 or N, where no more than two of X 2 -X 6 are N;
W is C 4 -C 10 cycloalkyl substituted with one or two substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, —OC 1 -C 6 alkyl, —O—C 3 -C 10 cycloalkyl, —CF 3 , and fluoro;
R 1 and R 11 are independently hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, —OC 1 -C 6 alkyl-O—C 1 -C 10 cycloalkyl, —O—C 1 -C 10 heterocycloalkyl, —O—C(R 12 )(R 13 )—C 1 -C 10 heterocycloalkyl, —O-aryl, —O-heteroaryl, —O—C(R 12 )(R 13 )-aryl, or —O—C(R 12 )(R 13 )-heteroaryl;
R 2 and R 6 are independently hydrogen, F, Br, I, —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 F, C 2 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, —OC 1 -C 6 alkyl, —-O—C 3 -C 10 cycloalkyl, —CN, aryl, or heteroaryl;
R 3 and R 5 are independently hydrogen, halogen, —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 F, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, —OC 1 -C 6 alkyl, —O—C 3 -C 10 cycloalkyl, —CN, aryl, or heteroaryl;
R 4 is hydrogen, F, Cl, Br, I, —CF 3 , —CN, —OCHF 2 , —OCH 2 F, —OCF 3 , C 1 -C 10 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, —OC 1 -C 10 alkyl, —OC 3 -C 10 cycloalkyl, —OC 3 -C 10 heterocycloalkyl, —SC 1 -C 10 alkyl, —SC 3 -C 10 cycloalkyl, aryl, or heteroaryl;
R 12 and R 13 each represent independently for each occurrence H, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl;
n is 1, 2, or 3;
where at least one of R 2 , R 3 , R 4 , R 5 , and R 6 is not hydrogen;
where R 3 is not morpholino or pyridyl; and
where if R 4 is —CH 3 , —OCF 3 , —OCH 3 , F, or Cl, then W is not unsubstituted cyclohexyl or unsubstituted cyclopropyl, or R 1 is not hydrogen.
2. The compound of claim 1 , wherein X 2 is CR 2 , X 3 is CR 3 or N, X 4 is CR 4 , X 5 is CR 5 , and X 6 is CR 6 .
3. The compound of claim 1 , wherein W is C 4 -C 10 cycloalkyl substituted with one or two substituents independently selected from the group consisting of C 1 -C 6 alkyl and fluoro.
4. The compound of claim 1 , wherein W is cyclohexyl substituted with C 1 -C 6 alkyl.
5. The compound of claim 1 , wherein R 1 and R 11 are independently hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocycloalkyl, —OC 1 -C 6 alkyl, —O—C 3 -C 10 cycloalkyl, —O—C 3 -C 10 heterocycloalkyl, or —O—C(R 12 )(R 13 )—C 3 -C 10 heterocycloalkyl.
6. The compound of claim 1 , wherein R 1 is methoxy, ethoxy, propoxy, t-butoxy, cyclobutoxy, morpholinyl, —O-tetrahydrofuranyl, —O—CH 2 -tetrahydrofuranyl, —O-tetrahydropyranyl, —O—CH 2 -tetrahydropyranyl, —O-oxetanyl, —O—CH 2 -oxetanyl, phenoxy or benzyloxy; and R 11 is hydrogen or methyl.
7. The compound of claim 1 , wherein R 2 and R 6 are hydrogen.
8. The compound of claim 1 , wherein R 3 and R 5 are hydrogen or halogen.
9. The compound of claim 1 , wherein R 4 is —CF 3 , —OCHF 2 , —OCH 2 F, —OCF 3 , C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, —OC 1 -C 6 alkyl, —OC 3 -C 10 cycloalkyl, or —OC 3 -C 10 heterocycloalkyl.
10. The compound of claim 1 , wherein the compound is represented by formula Ia:
including a pharmaceutically acceptable salt thereof, wherein:
X 2 is CR 2 , X 3 is CR 3 , X 4 is CR 4 , X 5 is CR 5 , and X 6 is CR 6 ;
W is C 4 -C 10 cycloalkyl substituted with one or two substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, —OC 1 -C 6 alkyl, —O—C 3 -C 10 cycloalkyl, —CF 3 , and fluoro;
R 1 and R 11 are independently hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, —OC 1 -C 6 alkyl, or —O—C 3 -C 10 cycloalkyl;
R 2 and R 6 are independently hydrogen, F, Br, I, —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 F, —OC 1 -C 6 alkyl, or —O—C 3 -C 10 cycloalkyl;
R 3 and R 5 are independently hydrogen, halogen, —CF 3 , —OCF 3 , —OCHF 2 , —OCH 2 F, —OC 1 -C 6 alkyl, or —O—C 3 -C 10 cycloalkyl; and
R 4 is F, Cl, Br, I, —CF 3 , —CN, —OCHF 2 , —OCH 2 F, —OCF 3 , C 3 -C 10 heterocyclyl, —OC 1 -C 6 alkyl, —OC 3 -C 10 cycloalkyl, or heteroaryl.
11. The compound according to claim 10 , wherein at least one of R 1 and R 11 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, and —O—C 3 -C 10 cycloalkyl.
12. The compound of claim 10 , wherein at least one of R 1 and R 11 is selected from the group consisting of hydrogen, —CH 3 , —OCH 3 , —O-isopropyl, —O-t-butyl, and —O-cyclobutyl.
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.